NuCana plc American Depositary Share (NCNA) Stock Price

NCNAStock
$0.99−80.74%52W
Market Cap$4.12M
P/E—
PEG Ratio—
Div yield—
Beta2.45

NCNA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-64.07%
Price vs S&P 500 (4W)-23.67%
VGM Score30.09

NCNA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q4 2024-$586.43-$86.43+85.26%(+$500.00)
Q3 2024-$1052.90-$585.89+44.35%(+$467.01)
Q2 2024-$1063.57-$1028.65+3.28%(+$34.92)
Q1 2024-$1092.89-$1097.69-0.44%(-$4.80)

NCNA Analyst Recommendations

Mar 2025
Apr 2025
May 2025
Jun 2025
4.00
4.13
4.13
4.13

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
NCNANuCana plc American Depositary Share
——D————$0.99
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About NuCana plc American Depositary Share

NuCana PLC is a biopharmaceutical company developing cancer treatments based on its proprietary ProTide technology, which delivers higher concentrations of anti-cancer metabolites to tumor cells to overcome drug resistance. The company's pipeline comprises three candidates—NUC-3373, NUC-7738, and Acelarin—with primary operations in the United States.